Fredrikson and shareholder Sean Solberg are proud to work with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) to protect its impressive technologies and are looking forward to helping further expand its patent portfolio in the future.
I am pleased to announce that NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has further strengthened its intellectual property portfolio with recent decisions from both the U.S. Patent & Trademark Office and the European Patent Office. These include our first granted European patent, an issued U.S. patent, and a Notice of Allowance in the U.S. Together, they represent meaningful progress in protecting and expanding our technology platform focused on improving surgical care for patients with neurological disorders. Temperature control remains an important component of our OneRF Ablation System, providing an added measure of safety for brain ablations in patients with seizures. The newly granted European patent covers a percutaneously placed paddle electrode designed to treat lower back pain without requiring a surgical incision. These advancements reinforce our commitment to innovation and clinical progress as we continue to expand the scope and impact of our technology. Full press release: https://lnkd.in/g-fxPqcW #nasdaq #NMTC